Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2009
Business Overview: Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference (RNAi). The company focuses on discovering, developing, and commercializing RNAi therapeutics through strategic alliances and its own research. As of the reporting date, the company had no commercial products on the market and had not achieved profitability.
Key Financial Metrics
| Metric | 2009 | 2008 |
|---|---|---|
| Net Revenues | $100.5 million | $96.2 million |
| Operating Expenses | $148.6 million | $124.0 million |
| Research & Development (R&D) | $108.7 million | $96.9 million |
| General & Administrative (G&A) | $39.9 million | $27.1 million |
| Net Loss | $(47.6) million | $(26.2) million |
| Net Loss Per Share (Basic/Diluted) | $(1.14) | $(0.64) |
| Cash, Cash Equivalents & Marketable Securities | $435.3 million | $512.7 million |
| Working Capital | $182.8 million | $343.7 million |
| Accumulated Deficit | $(299.8) million | $(252.2) million |
Note: The filing text does not provide specific data for debt or liquidity ratios beyond the cash balance and working capital figures listed above. The company had no notes payable outstanding as of December 31, 2009.
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased by approximately 4.5% to $100.5 million, driven primarily by a full year of revenue recognition from the May 2008 alliance with Takeda and higher revenues from the Roche alliance due to a development milestone achieved in 2009.
- Expense Increases: Operating expenses rose by 20% to $148.6 million. R&D expenses increased by 12% due to higher clinical trial and manufacturing costs for the ALN-TTR and ALN-VSP programs. G&A expenses surged by 47%, primarily due to increased legal fees related to patent litigation.
- Net Loss Expansion: The net loss widened significantly from $26.2 million in 2008 to $47.6 million in 2009, reflecting the increase in operating expenses outpacing revenue growth.
- Interest Income Decline: Interest income dropped from $14.4 million in 2008 to $5.4 million in 2009 due to significantly lower average interest rates.
Guidance, Outlook, and Risks
Management Commentary and Outlook
Management expects to continue incurring annual net operating losses over the next several years as it expands efforts to discover, develop, and commercialize RNAi therapeutics. The company anticipates that revenues will continue to be derived primarily from strategic alliances (Roche, Takeda, Novartis, Cubist), government contracts, and licensing activities. Based on current operating plans, management believes existing cash and marketable securities, combined with expected cash from alliances, will be sufficient to fund operations for at least the next several years.
Key Risks and Contingencies
- Patent Litigation: The company is engaged in significant legal action against Whitehead Institute, MIT, and UMass regarding the prosecution of the "Tuschl I" patent applications. A trial was expected to begin in June 2010. The outcome is uncertain and could materially affect the company's intellectual property portfolio.
- Development Risks: The company has no approved products. Success depends on the safety and efficacy of its clinical candidates (ALN-RSV01, ALN-VSP, ALN-TTR01) and the ability to overcome delivery challenges.
- Dependence on Collaborators: A substantial portion of revenue and future funding relies on the performance and continued commitment of major partners like Roche, Takeda, and Novartis.
- Capital Requirements: The company will require substantial additional funds to complete R&D activities. If additional funds are not available, operations may need to be scaled back.
Important Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $435.3 million cash balance against the projected burn rate, given the company's history of losses and lack of product revenue.
- Patent Litigation Status: Monitor the outcome of the lawsuit against Whitehead/MIT/UMass, as the company's business model relies heavily on its exclusive patent rights in the RNAi field.
- Clinical Trial Progress: Track the results of the Phase IIb trial for ALN-RSV01 (initiated Feb 2010) and the Phase I trials for ALN-VSP and ALN-TTR01, as these are critical for future commercialization.
- Revenue Recognition Policies: Review the deferred revenue balances ($271.8 million total) and the specific accounting treatments for alliances with Roche, Takeda, and Cubist, as revenue is recognized over long periods (5-8 years) rather than upfront.
- Regulus Therapeutics Investment: Assess the performance of the company's 49% equity investment in Regulus Therapeutics, which contributed a $4.9 million loss to the 2009 results.